A PHASE 1B/2 STUDY OF IMATINIB IN COMBINATION WITH EVEROLIMUS IN SYNOVIAL SARCOMA (NCI #8603).

Trial Profile

A PHASE 1B/2 STUDY OF IMATINIB IN COMBINATION WITH EVEROLIMUS IN SYNOVIAL SARCOMA (NCI #8603).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Everolimus (Primary) ; Imatinib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Jul 2013 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 10 Apr 2013 Planned end date changed from 1 Feb 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 06 Nov 2012 Planned End Date changed from 1 Jun 2014 to 1 Feb 2013, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top